2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1772

Better Cost-Effectiveness and Worker Productivity In Triple DMARD Therapy Versus Methotrexate Monotherapy In Early Rheumatoid Arthritis; Cost-Utility Analysis Of The Treach Trial
Abstract Number: 1764

Binding Of Apoptotic Fetal Cardiocytes By Anti-Ro Antibodies Stimulates uPA/uPAR- Dependent Macrophage Infiltration and M2 Type Phenotype
Abstract Number: 1955

Biochemical MRI With Gagcest (Glycosaminoglycan Chemical Exchange Saturation Transfer Imaging) Of Finger Joint Cartilage In Rheumatoid Arthritis
Abstract Number: 466

Biologic Monotherapy in French Rheumatoid Arthritis (RA) Patients From a Real-Life Clinical Practice Compared To Patients Treated with a Combination Therapy (Biologic + DMARD)
Abstract Number: 2338

Biologic Switching Rates Among Patients With Rheumatoid Arthritis
Abstract Number: 2036

Biologic Therapy For Relapsing Polychondritis: Old and New Efficacy Indices
Abstract Number: 2625

Biologic Therapy In Refractory Uveitis Of Behcet’s Syndrome: Switching and Dose Modification. Multicenter Study Of 124 Patients
Abstract Number: 2013

Biologic Therapy In Refractory Uveitis Of Sarcoidosis. Multicenter Study Of 16 Patients
Abstract Number: 1707

Biological Insights From Genetics Of Rheumatoid Arthritis Contribute To Drug Discovery
Abstract Number: 2874

Biological Roles of C5orf30 In Rheumatoid Arthritis Synovial Fibroblasts
Abstract Number: 2057

Biomarker and Serologic Predictors Of Clinical Improvement After B Cell Depletion In Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM) – The RIM (Rituximab in Myositis) Trial
Abstract Number: 2377

Biomarkers Associated With Rheumatoid Arthritis Disease Activity Including Joint Damage Correlate With Changes In Clinical Response In Subjects Treated With Mavrilimumab At Doses Above 10 Mg
Abstract Number: 249

Biomarkers Reflect Differences In Osteoarthritis Phenotypes Of The Lumbar Spine: The Johnston County Osteoarthritis Project
Abstract Number: 2161

Biopsychosocial Typologies of Pain in a Cohort of Patients With Systemic Sclerosis
Abstract Number: 2618

Bipolar Disorders May Represent a Primary Feature Of Behçet’s Disease

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].